reason report
earn tiara clinic trial continu progress pt
bottom line yesterday afternoon nvcn report sale
still solid reduc sale -- contribut revenu
y/i tiara implant continu ramp patient
vs februari novemb august enrol
either compassion use feasibl enrol expect
acceler addit site open underwritten
offer novemb includ common share
warrant senior secur convert note
pay damag nvcn exit cash posit
suffici fund day-to-day oper next
month continu tiara clinic studi view due
share price mechan associ fundrais nvcn saw
signific dilut share count common share
issu outstand today potenti even meaning
dilut remain seri warrant seri warrant
share remain trade novemb amount
dilut depend futur stock price compani note
fulli dilut share could assum exercis
close price yesterday still view posit materi
uncertainti remov believ nvcn share
move meaning higher given tiara statu front-runn
race first-to-market tmvr transcathet mitral valv
replac devic address market peg
reiter op pt point believ solvenc risk
larg mitig lower price target -- --
reflect signific dilut downsid upsid high
view believ risk/reward favor lower
price target reflect averag believ possibl
royalti rate rang royalti pay-out conserv
scenario point view
clinic progress tiara enrol like acceler nvcn
report total number implant reach patient
includ tiara ii ce mark trial februari
novemb august late-may mid-march overal
surviv rate patient follow
day longest follow-up patient four year nvcn expect
implant momentum acceler new center come line
manag confid ce mark trial fulli
enrol beyond tiara nvcn initi cosira ii studi
 patient center
medic suppli devic
scenario discount rate
compani inform leerink partner llc research
revenu million ep
pleas refer page import disclosur price chart analyst certif
rate nvcn share outperform price target though still earli
develop believ neovasc verg tap dramat larg
potenti high growth transcathet mitral valv replac tmvr market tiara
technolog neovasc tiara current forefront still nascent develop
market total number implant reach patient either feasibl
compassion use mitral regurgit mr preval aortic stenosi
tmvr clearli repres massiv virtual unpenetr market opportun peg
global tmvr market opportun assum tmvr initi target function mr patient
high risk surgeri almost tripl current transcathet aortic valv
replac tavr market estim use tavr proxi clear demand
less invas transcathet therapi high valvular diseas patient mr particularli
sever mr repres highli underserv patient popul poor surgic outcom
drive surgic penetr rate less total market tiara clearli
without risk given earli stage develop medacorp physician check suggest
tiara repres highli viabl solut given anatom d-shape leaflet independ
anchor mechan next month tiara pois hit number clinic
mileston investor abl gaug develop progress upon
nvcn share like react includ
complet enrol on-going feasibl studi ou
studi least patient alreadi enrol
feasibl studi data potenti late-break spring medic meet measur
procedur success outcom mace follow-
initi ce mark trial late upon feasibl studi complet ce mark approv
possibl earli
 pivot studi upon complet on-going feasibl studi
believ neovasc deliv compound annual top-lin growth
see potenti upsid alreadi top-tier sale growth profil driven
rapid aggress tmvr market develop europ
model assum fairli modest penetr rate address market sever year
launch european penetr penetr
potenti competit setback current assum neovasc edward secur
eu approv time fast follow howev
high probabl one competitor could face clinic setback fail reach
market
potenti faster ww tmvr market growth potenti market expans either
degen mr and/or moder risk patient popul model current assum
tmvr address function patient high risk surgeri
next month believ nvcn share trade arriv price target
use discount cash flow dcf analysi take averag valuat base rang
royalti rate dcf use discount rate probability-
weight believ dcf appropri consid neovasc expect sale inflect
point tiara potenti ce mark approv earli potenti approv
launch acknowledg small-cap med-tech compani valu base
compar compani ev/sal multipl believ dcf best captur total address
market opportun neovasc tiara tmvr market estim potenti
risk neovasc rate valuat includ possibl tiara and/or reduc
approv us and/or europ commerci ramp tiara and/or reduc fail
meet expect challeng fda approv pathway tiara and/or reduc
fairli robust competit landscap mr replac pipelin on-going trademark
potenti patent litig potenti reimburs risk failur obtain suffici
reimburs tiara and/or reduc secur approv
canadian dollar million except ep
loss foreign exchang
revenu
estimate
compani report leerink partner estim
canadian dollar million except ep
compani report leerink partner estim
estimate
neovasc outlook estim chang overview
canadian dollar million except ep
loss foreign exchang
revenu
compani report leerink partner estim
neovasc sale outlook estim chang overview
canadian dollar million except ep
compani report leerink partner estim
canadian dollar million except ep
good sold
loss foreign exchang
basic averag share thousand
good sold sale
sg sale ex med-tech tax
 sale
oper expens sale
good sold
basic dilut ep
compani report leerink partner estim
